Enzon Opens a Phase 2 Study of PEG-SN38 for Metastatic Breast Cancer
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Enzon Pharmaceuticals, Inc. announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer.
PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).
The study is designed to evaluate the efficacy of single-agent PEG-SN38 in two groups of patients who have received prior therapy regimens of anthracycline and taxane or anthracycline, taxane and Xeloda. The PEG-SN38 compound is currently being evaluated in a Phase 2 study for metastatic colorectal cancer.
“We continue to be encouraged by our PEG-SN38 compound and are pleased to be advancing it into additional areas of cancer”
"We continue to be encouraged by our PEG-SN38 compound and are pleased to be advancing it into additional areas of cancer,” said Jeffrey H. Buchalter, Enzon's president and chief executive officer. "We look forward to providing updates on PEG-SN38 and the rest of our novel pipeline as data becomes available.”
“Irinotecan is known to be active in metastatic breast cancer but toxicity has limited its broad use. We are very excited about evaluating the novel PEG-SN38 compound in hopes that it will exhibit an improved treatment for metastatic breast cancer patients,” said Dr Joyce O'Shaughnessy, Baylor-Charles A. Sammons Cancer Center.
PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).
The study is designed to evaluate the efficacy of single-agent PEG-SN38 in two groups of patients who have received prior therapy regimens of anthracycline and taxane or anthracycline, taxane and Xeloda. The PEG-SN38 compound is currently being evaluated in a Phase 2 study for metastatic colorectal cancer.
“We continue to be encouraged by our PEG-SN38 compound and are pleased to be advancing it into additional areas of cancer”
"We continue to be encouraged by our PEG-SN38 compound and are pleased to be advancing it into additional areas of cancer,” said Jeffrey H. Buchalter, Enzon's president and chief executive officer. "We look forward to providing updates on PEG-SN38 and the rest of our novel pipeline as data becomes available.”
“Irinotecan is known to be active in metastatic breast cancer but toxicity has limited its broad use. We are very excited about evaluating the novel PEG-SN38 compound in hopes that it will exhibit an improved treatment for metastatic breast cancer patients,” said Dr Joyce O'Shaughnessy, Baylor-Charles A. Sammons Cancer Center.